FDA Brief

Warning letters Drugs

FDA warning letter to

Sircle Laboratories, LLC

MediumIssued Sep 21, 2021Posted Oct 19, 2021Office of Pharmaceutical Quality Operations, Division II

Sircle Laboratories' drugs are adulterated (not meeting legal quality standards) due to poor CGMP (manufacturing quality rule) oversight of contract manufacturers (outside makers).

What happened

FDA inspected Sircle's drug manufacturing facility in Madison, Mississippi, from April 13 to 26, 2021. FDA found that the quality unit (the group responsible for drug quality decisions) did not adequately oversee contract manufacturers, lacked written procedures for approving or rejecting batches, did not follow its own procedure for managing changes, and failed to establish or follow adequate complaint-handling and labeling procedures. FDA said Sircle's May 11, 2021 response was inadequate and noted similar violations in 2015 and 2019 inspections.

What FDA found

  1. The quality unit failed to oversee contract manufacturers and ensure drugs met specifications.

    21 CFR 211.22
  2. FDA found no adequate written procedure for approving or rejecting batches made by a contract manufacturer.

    21 CFR 211.22
  3. The company changed complaint, recall and labeling procedures without following its own procedure for managing changes.

    21 CFR 211.22
  4. The complaint-handling procedure named staff positions that did not exist and did not ensure quality complaints were investigated.

    21 CFR 211.198(a)
  5. The labeling review procedure did not require checking all label elements or comparing labels to a master label.

    21 CFR 211.130

What FDA wants

FDA asks Sircle to respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence, including comprehensive assessments and remediation plans for supplier oversight, quality unit authority, complaints, labeling and CAPA. If corrective actions cannot be completed in that time, the company must state why and give a completion schedule.

Who should pay attention

  • brands that use Sircle or its contract manufacturers for finished drugs
  • quality teams managing contract manufacturers and batch release
  • companies handling drug complaints and labeling

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk